Publications

Browse recent peer-reviewed articles reporting the results of Kite-sponsored clinical trials. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Review articles are excluded. Clinical decisions should be based on the full safety and efficacy information contained in the products’ Full Prescribing Information in the link provided next to the products’ names.

If you have questions a Kite-sponsored clinical trial not listed below or would like to request an electronic copy of the journal publication on this page, please contact Kite Medical Information below for further assistance.

Product

Disease State

Select a product to view publications

By clicking the below links, you will be leaving the Kite Medical Information website and will be redirected to a third-party site. We do not control, endorse, or influence the claims or comments in the following third-party website.


Publication
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Publication Date: December 28, 2017
Author: Neelapu, S
Yescarta | DLBCL
Publication
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Publication Date: December 28, 2016
Author: Locke, F
Yescarta | DLBCL
Publication
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Publication Date: July 13, 2023
Author: Locke, F
Yescarta | DLBCL
Publication
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Publication Date: August 1, 2023
Author: Shah, B
Tecartus | ALL
Publication
Outcomes of Axicabtagene Ciloleucel Versus Standard of Care in Patients 65 Years of Age or Older With Relapsed/Refractory Large B-Cell Lymphoma
Publication Date: April 27, 2023
Author: Westin, J
Yescarta | DLBCL
Publication
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Publication Date: August 7, 2021
Author: Shah, B
Tecartus | ALL
Publication
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Publication Date: February 17, 2022
Author: Locke, F
Yescarta | DLBCL
Publication
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Publication Date: July 9, 2021
Author: Shah, B
Tecartus | ALL
Publication
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
Publication Date: September 1, 2022
Author: Ghione, P
Yescarta | FL
Publication
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
Publication Date: January 10, 2024
Author: Hess, G
Tecartus | MCL

Call

Kite Medical Information

For product inquiries, adverse events, and products complaints, please call 1-844-454-KITE (1-844-454-5483), Monday-Friday, 5:00am-6:00pm US PST.

Offcanvas title

[contact-form-7 id="508a1ec" title="Submit Medical Inquiry"]